Results 11 to 20 of about 53,817 (192)

Erlotinib-Associated Acute Pneumonitis: Report of Two Cases [PDF]

Canadian Respiratory Journal, 2007
Two cases of erlotinib-associated acute pneumonitis are described. The first patient was started on erlotinib treatment for metastatic non-small cell lung cancer.
Bobbak Vahid, Ali Esmaili
doaj   +2 more sources

Quantitation of Cirtuvivint (SM08502) in Human Plasma by LC-MS/MS. [PDF]

Biomed Chromatogr
ABSTRACT CDC‐like kinases (CLK) and dual‐specificity tyrosine‐regulated kinases (DYRK) are protein kinases involved in various cellular functions, mRNA splicing, and DNA damage repair. CLK/DYRK kinases have been implicated in many disorders such as diabetes, neurodegenerative diseases, and cancer.
Holleran JL, Deppas JJ, Feng Y, Hochman MJ, Chen EC, Stahl M, Gore SD, Synold TW, Beumer JH, Venkataramanan R, Parise RA.   +10 more
europepmc   +2 more sources

First‐Line Osimertinib in Patients with EGFR‐Mutant Advanced Non‐Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study

The Oncologist, EarlyView., 2021
Abstract Lessons Learned Osimertinib has confirmed effectiveness in this real‐world population of patients with EGFR‐mutant advanced non‐small cell lung cancer. Thromboembolic events occur more frequently than previously reported, suggesting a thrombotic diathesis that requires further investigation. Patients with at least three metastatic sites, brain
Martina Lorenzi, Alessandra Ferro, Fabiana Cecere, Daniela Scattolin, Alessandro Del Conte, Alessandro Follador, Sara Pilotto, Valentina Polo, Mariacarmela Santarpia, Rita Chiari, Alberto Pavan, Alessandro Dal Maso, Valentina Da Ros, Giada Targato, Sabrina Vari, Stefano Indraccolo, Fiorella Calabrese, Stefano Frega, Laura Bonanno, Pier Franco Conte, Valentina Guarneri, Giulia Pasello   +21 more
wiley   +1 more source

Erlotinib in patients with previously irradiated, recurrent brain metastases from non-small cell lung cancer: Two case reports [PDF]

, 2008
Background: With the current improvements in primary lung care, the long-term control of brain metastases becomes a clinical challenge. No established therapeutic approaches exist for cranial relapse after response to previous radiotherapy and systemic ...
Pawel, Joachim, Wagner, Horst, Poellinger, Barbara, Duell, Thomas   +3 more
core   +1 more source

The Role of ARL4C in Erlotinib Resistance: Activation of the Jak2/Stat 5/β-Catenin Signaling Pathway

Frontiers in Oncology, 2020
Cancer patients who initially benefit from Erlotinib, a drug targeting EGFR path, eventually develop resistance to the drug. The underlying mechanism is largely unknown.
Jinrong Liao, Zeng Chen, Zongyang Yu, Tao Huang, Dan Hu, Ying Su, Zhiyong He, Changyan Zou, Lurong Zhang, Xiandong Lin, Xiandong Lin   +10 more
doaj   +1 more source

Challenges of drug resistance in the management of pancreatic cancer [PDF]

, 2010
The current treatment of choice for metastatic pancreatic cancer involves single agent gemcitabine or combination of gemcitabine with capecitabine and erlotinib (tyrosine kinase inhibitor).
Naomi Walsh, Martin Clynes, Rizwan Sheikh, Sheikh, Rizwan, O'Connor, Robert A., Robert O’Connor, Ray McDermott, O'Connor, Robert, Clynes, Martin, Walsh, Naomi, McDermott, Ray   +10 more
core   +1 more source

Disclosure of Erlotinib as a Multikinase Inhibitor in Pancreatic Ductal Adenocarcinoma

Neoplasia: An International Journal for Oncology Research, 2011
A placebo-controlled phase 3 trial demonstrated that the epidermal growth factor receptor (EGFR) inhibitor erlotinib in combination with gemcitabine was especially efficient in a pancreatic ductal adenocarcinoma (PDAC) subgroup of patients developing ...
Laura Conradt, Klaus Godl, Christoph Schaab, Andreas Tebbe, Stefan Eser, Sandra Diersch, Christoph W. Michalski, Jörg Kleeff, Angelika Schnieke, Roland M. Schmid, Dieter Saur, Günter Schneider   +11 more
doaj   +1 more source

Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer

ERJ Open Research, 2022
Introduction Previous studies have shown interference between epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and chemotherapy in the cell cycle, thus reducing efficacy.
Rolof G.P. Gijtenbeek, Vincent van der Noort, Joachim G.J.V. Aerts, Jeske A. Staal-van den Brekel, Egbert F. Smit, Frans H. Krouwels, Frank A. Wilschut, T. Jeroen N. Hiltermann, Wim Timens, Ed Schuuring, Joost D.J. Janssen, Martijn Goosens, Paul M. van den Berg, A. Joop de Langen, Jos A. Stigt, Ben E.E.M. van den Borne, Harry J.M. Groen, Wouter H. van Geffen, Anthonie J. van der Wekken   +18 more
doaj   +1 more source

Erlotinib in the treatment of advanced pancreatic cancer [PDF]

, 2008
Robin K Kelley, Andrew H KoUniversity of California, San Francisco, Comprehensive Cancer CenterAbstract: Single agent gemcitabine has been the mainstay of therapy for advanced pancreatic cancer over the past decade.
Andrew H Ko, Kelley, Robin K, Robin K Kelley, Ko, Andrew H   +3 more
core   +1 more source

Upregulated interleukin‐6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma

Molecular Oncology, 2015
Despite the role of epidermal growth factor receptor (EGFR) signaling in head and neck squamous cell carcinoma (HNSCC) development and progression, clinical trials involving EGFR tyrosine kinase inhibitors (TKIs) have yielded poor results in HNSCC ...
Aditya Stanam, Laurie Love-Homan, Tisha S. Joseph, Madelyn Espinosa-Cotton, Andrean L. Simons   +4 more
doaj   +1 more source